What are the clinical presentations, causative organisms, and recommended management for common sexually transmitted infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Presentations, Causative Organisms, and Management of Sexually Transmitted Infections

The most common STIs present with distinct clinical patterns: urethritis/cervicitis (gonorrhea, chlamydia), genital ulcers (syphilis, herpes), vaginal discharge (trichomoniasis), and genital warts (HPV), with treatment centered on ceftriaxone for gonorrhea, doxycycline for chlamydia, penicillin for syphilis, and metronidazole for trichomoniasis 1, 2.

Key Clinical Presentations by Organism

Chlamydia trachomatis

  • Clinical Picture: 53-100% of infections are asymptomatic or minimally symptomatic 1. When symptomatic, presents as mucopurulent cervicitis in women or urethritis in men with dysuria and urethral discharge
  • High-risk populations: Women <25 years, new or multiple sex partners, unprotected sex 3
  • Complications: PID, ectopic pregnancy, infertility, with some women having subclinical upper reproductive tract infection even with uncomplicated cervical infection 3
  • Management: Doxycycline 100 mg orally twice daily for 7 days is the preferred treatment 2. Alternative: Azithromycin 1 g orally single dose 3

Neisseria gonorrhoeae

  • Clinical Picture: 53-100% of extragenital infections are asymptomatic 1. Symptomatic cases present with purulent urethral/cervical discharge, dysuria
  • Extragenital sites: Pharyngeal and rectal infections common, especially in high-risk populations 4
  • Management: Ceftriaxone monotherapy intramuscularly, with dosing based on body weight 2. Concurrent treatment for chlamydia indicated if prevalence >5% in the patient population 3
  • Test-of-cure required: For all pharyngeal gonorrhea cases 2

Treponema pallidum (Syphilis)

  • Clinical Picture:
    • Primary: Painless genital ulcer (chancre)
    • Secondary: Rash (including palms/soles), lymphadenopathy, condyloma lata
    • Latent: Asymptomatic
    • Tertiary: Cardiovascular, gummatous, neurologic complications
  • Critical evaluation: Thorough assessment for otic, ophthalmic, and neurologic symptoms essential at any stage 2
  • Management:
    • <1 year duration: Single dose penicillin G benzathine 2.4 million units IM 2
    • >1 year or unknown duration: Three consecutive weekly doses of penicillin G benzathine 2.4 million units IM 2
    • Neurosyphilis requires 10-14 days IV aqueous crystalline penicillin G 2

Trichomonas vaginalis

  • Clinical Picture: 70% asymptomatic 1. Symptomatic cases present with frothy, malodorous vaginal discharge, vulvovaginal irritation, dysuria
  • Management: Seven-day regimen of metronidazole (not single-dose) 2

Herpes Simplex Virus (HSV-1 and HSV-2)

  • Clinical Picture: Painful grouped vesicles on erythematous base, progressing to ulcers. Primary infection more severe than recurrences
  • Diagnosis: Nucleic acid amplification tests have 86.1-100% sensitivity for symptomatic HSV 1
  • Management: No cure available; antiviral therapy for symptom management 1

Mycoplasma genitalium

  • Clinical Picture: Urethritis, cervicitis similar to chlamydia
  • Management: Moxifloxacin, though antimicrobial resistance limits oral treatment options 1, 4

Diagnostic Approach

Testing Methods

  • Nucleic acid amplification tests (NAATs): 86.1-100% sensitivity and 97.1-100% specificity for gonorrhea, chlamydia, M. genitalium, trichomoniasis, and symptomatic HSV 1
  • Syphilis: Serology remains standard—sequential testing for treponemal and nontreponemal antibodies 1
  • Extragenital screening: Consider pharyngeal and rectal testing for gonorrhea/chlamydia in high-risk women 4

Screening Recommendations

  • Chlamydia: Annual screening for all sexually active women <25 years and older women with risk factors 3
  • Syphilis: Screen three times during pregnancy (first visit, third trimester, delivery) regardless of risk 4. Screen reproductive-aged persons in counties with primary/secondary syphilis rates >4.6 per 100,000 4

Critical Management Principles

Partner Management

Sex partners must be notified, examined, and treated for identified or suspected STDs 3. Patients and partners should abstain from sexual intercourse for 7 days after single-dose regimen or until completion of 7-day regimen 3.

Concurrent Infections

Any STI increases risk of acquiring other STIs, including HIV 1, 5. Evaluate for multiple infections simultaneously. Concurrent trichomoniasis or bacterial vaginosis should be treated if detected 3.

Antimicrobial Resistance

Increasing resistance limits oral treatment options for gonorrhea and M. genitalium 1. This necessitates IM ceftriaxone for gonorrhea rather than oral alternatives.

Persistent Cervicitis

For women with persistent cervicitis after treatment, reevaluate for reexposure, reassess vaginal flora, and ensure partners were treated 3. If relapse/reinfection excluded and bacterial vaginosis absent, management options are undefined; ablative therapy may be considered by gynecologic specialist 3.

Common Pitfalls

  • Underdiagnosing asymptomatic infections: Most chlamydia, trichomoniasis, and extragenital gonorrhea cases lack symptoms—rely on screening protocols 1
  • Missing extragenital sites: Pharyngeal and rectal infections frequently missed without site-specific testing 4
  • Inadequate partner treatment: Failure to treat partners leads to reinfection 3
  • Wrong trichomoniasis regimen: Single-dose metronidazole no longer recommended; use 7-day course 2
  • Missing neurosyphilis: Failure to assess for neurologic, otic, or ophthalmic symptoms can miss complications requiring different treatment duration 2

References

3
Guideline

sexually transmitted diseases treatment guidelines, 2006.

MMWR Recommendations and Reports, 2006

4
Research

Clinical Updates in Sexually Transmitted Infections, 2024.

Journal of women's health (2002), 2024

Related Questions

For a patient diagnosed with chlamydia and trichomoniasis, what medications should be prescribed and what is the duration of therapy?
What is the recommended treatment for a teenage male with suspected sexually transmitted infections such as chlamydia, gonorrhea, syphilis, or genital herpes?
Do Sexually Transmitted Infections (STIs) require different treatment regimens based on the patient's sex, male versus female?
Given that my STI panel—including chlamydia, gonorrhea, HIV, syphilis, HSV‑1/2, hepatitis A/B/C, trichomoniasis, and Mycoplasma genitalium—was negative on [DATE], what does this mean and what follow‑up care is recommended?
What are the first‑line treatment regimens for common sexually transmitted infections such as chlamydia, gonorrhea, syphilis, trichomoniasis, genital herpes, and HPV‑related genital warts?
What clinical and laboratory features define a very high‑risk non‑ST‑segment elevation myocardial infarction (NSTEMI)?
Which of the following findings—tea-colored urine, bleeding, abdominal pain, worsening malaise, or high-grade fever—most likely signifies severe malaria in this patient?
In a 73-year-old male with a history of prostate cancer (stage III, Gleason score 7 [3+4]), diabetes mellitus, and hypertension, what is the expected disease progression and how long would it take without treatment?
What is the best treatment approach for a 73-year-old man with locally advanced (stage III) prostate cancer, Gleason 3 + 4, and comorbid diabetes and hypertension?
What are the differences between type I (slow‑twitch) and type II (fast‑twitch) fibers in pelvic floor muscles, and how should each be trained?
Why is ferritin elevated after a minimally invasive (laparoscopic) cholecystectomy and what evaluation is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.